Human microbiome industry definitely is a promising field to work with. According to Human Microbiome Market Report 2018, published in May, the industry has suffered a certain impact of global economic slow down, but still maintained a relatively optimistic growth, the past four years. Human Microbiome market size maintained the average annual growth rate of 22.67% from 130 million $ in 2014 to 240 million $ in 2017. BisReport analysts believe that in the next few years, the market size will be further expanded. They expect that by 2022, the market size of the HM market will reach 635 million $. If you need more information, please contact BisReport
Therapeutics market
This market is developing evidence-based microbiome modulators designed to shift bacterial populations and their environment in the gastrointestinal (GI) tract to better manage serious health conditions. Gastrointestinal tract (GIT) is an organ system that includes the mouth, esophagus, stomach, and the intestines. The GIT can be divided into upper Git and lower GIT. Upper GIT consists of the oral cavity, the pharynx, the esophagus, the stomach, and the duodenum. The lower GIT consists of the small and large intestines. Gastrointestinal disorders refer to diseases involving the GIT. Microbiome therapeutics are being increasingly adopted for the treatment of gastrointestinal disorders such as IBS and ulcerative colitis.
Industry analysts forecast the global human microbiome therapeutics Market to grow at a CAGR of 14.19% during the period 2018-2022. Leading Vendors of Human Microbiome Therapeutics Market Space: ENTEROME Bioscience, Rebiotix, Seres Therapeutics, Vedanta Biosciences, Bristol-Myers Squibb, Johnson & Johnson, and Takeda Pharmaceutical. If you need more information get a copy of sample report.
Promising venture
As one of the important market driver is side effects of the existing treatments, more and more companies are heading towards efficiency with fewer side effects, creating innovation in the field of probiotics. Last November, DuPont Nutrition & Health (DuPont), the global leader on nutrition, biosciences, and electronics announced the creation of its Microbiome Venture to spearhead development of new science-based solutions. Three months after its formation, the DuPont Nutrition & Health Microbiome Venture announced its second strategic research and development partnership with the Center of Food and Fermentation Technologies (TFTAK) in Tallinn, Estonia. The parntership will focus on developing cultivation and bioprocess capabilities for “next-generation” probiotics. If you need more information, please continue here.
